ORGO Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $42.8 million, a decline of 58% year-over-year.

Advanced Wound Care Revenue: $36.1 million, down 61% year-over-year.

Surgical & Sports Medicine Revenue: $6.7 million, down 18% year-over-year.

Net Loss: GAAP net loss of $96.3 million, compared to a net loss of $9.4 million in the prior year.

Adjusted EBITDA Loss: $34.4 million, worsening from a loss of $3.6 million year-over-year.

Cash Position: $46.8 million in cash and equivalents, down from $94.3 million at year-end 2025.

Operating Expenses: Decreased to $94.7 million from $113.6 million year-over-year, with significant reductions in SG&A expenses.

2Strategic Updates and Business Highlights

Market Position: Despite a challenging environment, ORGO reported a sequential revenue increase of 18% in Q2, driven by a 23% rise in Advanced Wound Care sales.

Product Development: The FDA accepted the biologic license application for Amnuvx, with a target action date set for April 2027. This product aims to address knee osteoarthritis and could create a new market category.

Clinical Evidence: Positive clinical trial results for PuraPly AM and Affinity were highlighted, supporting their inclusion in future coverage policies.

Restructuring: A workforce reduction of 138 employees was implemented, expected to save approximately $18 million annually, part of a broader strategy to reduce operating costs.

3Forward Guidance and Outlook

2026 Revenue Guidance: Updated to a range of $179 million to $215 million, reflecting a decline of 62% to 68% year-over-year, worse than previous expectations.

Sequential Growth: Anticipated modest growth in Q3 and stronger performance in Q4, with expectations for a nearly 60% reduction in adjusted EBITDA loss in the second half of 2026.

Operating Expense Reduction: Expected to decrease by approximately 32% year-over-year in 2026, with more than 40% reduction in the second half.

4Bad News, Challenges, or Points of Concern

Market Contraction: The skin substitute market continues to face significant contraction due to changes in CMS coverage and payment policies, impacting revenue.

Operating Losses: Substantial operating losses reported, with a notable increase in net loss attributed to non-cash tax expenses.

Cash Burn: The company is experiencing a significant decline in cash reserves, raising concerns about liquidity and operational sustainability.

Delayed Product Launches: The launch of Dermagraft is postponed to mid-2028 to conserve cash, indicating challenges in product development timelines.

5Notable Q&A Insights

Market Dynamics: Management expressed confidence in the stabilization of the market due to CMS's recent actions, which are expected to enhance clinician trust and product adoption.

Guidance Nuances: The guidance reflects conservative expectations for growth, with the low end accounting for slower growth than Q2 and the high end aligning with current growth rates.

Product Payment Concerns: There is apprehension regarding reimbursement for products without robust clinical evidence, which could lead to potential clawbacks post-audit.

Competitive Landscape: ORGO believes it is well-positioned against competitors due to its strong clinical evidence and product efficacy, particularly as other players exit the market. This summary encapsulates the key points from the earnings call, providing a balanced view of ORGO's current financial health, strategic direction, and market challenges.